|
|
 |
|
Viewing report
|
|
|
|
Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, July 2011, Pages: 53
Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Hyperthyroidism market. The report identifies the key trends shaping and driving the global Hyperthyroidism market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hyperthyroidism sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The global Hyperthyroidism therapeutics market was valued at $375m in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 2.9% to reach $459m in 2017. The growth of the market will be slow due to the dominance of generics and the lack of approved drugs. The primary factor driving the market is the increase in the elderly population. At present, the market is served by therapies such as antithyroid agents (methimazole, propylthiouracil, carbimazole), radioactive iodine and beta blockers used as an adjuvant therapy. The market is dominated by generics. As the disease is curable if identified in time, the unmet need is low. Despite the efficient therapies available for the indication, there are still some unmet needs that can be tapped by products with better efficacy and safety.
Scope
The report provides information on the key drivers and challenges of the Hyperthyroidism market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hyperthyroidism market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as anti-CD3, anti-CD20 and TSH mimicking.
- Analysis of the current and future competition in the seven key countries Hyperthyroidism market. Key market players covered are Genzyme (acquired by Sanofi) and GlaxoSmithKline.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hyperthyroidism therapeutics market.
- Analysis of key recent licensing and partnership agreements in Hyperthyroidism market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hyperthyroidism market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hyperthyroidism market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hyperthyroidism market landscape? – Identify, understand and capitalize.
|
|
|
|
